Business Context and Reporting Period
This Form 8-K Current Report was filed by Aclaris Therapeutics, Inc. on August 9, 2017. The filing reports the appointment of a new director and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Andrew Schiff to the Board of Directors, effective August 9, 2017. Dr. Schiff was also appointed to the Compensation Committee. His term as a Class I director expires at the 2019 annual meeting of stockholders.
Guidance, Outlook, and Compensation
There is no forward-looking guidance or management commentary regarding business operations in this filing. The document details the following compensatory arrangements for Dr. Schiff:
- Initial Stock Option: Grant of a nonqualified stock option to purchase 16,000 shares of common stock. The exercise price equals the closing price on the grant date. Vesting occurs in 36 equal monthly installments contingent on continuous service.
- Annual Retainers: $35,000 annual retainer for director service and $5,000 annual retainer for Compensation Committee service.
- Future Options: Entitlement to an additional nonqualified stock option to purchase 8,000 shares at each subsequent annual stockholder meeting, vesting in 12 equal monthly installments.
- Related Party Transactions: Dr. Schiff's firm, Aisling Capital IV, LP, purchased 405,405 shares in June 2016 for $7.5 million and 87,912 shares in November 2016 for $2.0 million. No other transactions exceeding $120,000 involving Dr. Schiff or his family have occurred since January 1, 2016.
Investor Verification Checklist
- Verify the closing stock price on August 9, 2017, to determine the exercise price of the initial 16,000 share option grant.
- Review the Company's 2015 Equity Incentive Plan to confirm the definition of "Continuous Service" required for vesting.
- Confirm the total outstanding share count to assess the dilution impact of the new option grants.
- Check subsequent filings for the formal ratification of Dr. Schiff's appointment at the next annual stockholder meeting.